Transglutaminase factor XIII promotes arthritis through mechanisms linked to inflammation and bone erosion

Blood

Volumn 125, Issue 3, 2015, Pages 427-437

  Raghu, Harini ^a   Cruz, Carolina ^a   Rewerts, Cheryl L ^a   Frederick, Malinda D ^a   Thornton, Sherry ^a   Mullins, Eric S ^a   Schoenecker, Jonathan G ^b   Degen, Jay L ^a   Flick, Matthew J ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 13; CYSTAMINE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; COLLAGEN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHROPATHY; ARTICLE; B LYMPHOCYTE; BONE DESTRUCTION; BONE EROSION; CARTILAGE; CARTILAGE DEGENERATION; CONTROLLED STUDY; FEMALE; IMMUNIZATION; INFLAMMATORY DISEASE; MALE; MONOCYTE MACROPHAGE PRECURSOR CELL; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; TISSUE REGENERATION; WILD TYPE; ANIMAL; BONE DISEASE; CELL CULTURE; CELL DIFFERENTIATION; CHEMICALLY INDUCED; COMPLICATION; DBA MOUSE; EXPERIMENTAL ARTHRITIS; GENETICS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; OSTEOCLAST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BLOTTING, WESTERN; BONE DISEASES; CELL DIFFERENTIATION; CELLS, CULTURED; COLLAGEN; FACTOR XIII; FEMALE; INFLAMMATION; MALE; MICE; MICE, INBRED DBA; MICE, KNOCKOUT; OSTEOCLASTS; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84922158986     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-594754     Document Type: Article

References (61)

1. Choi Y, Arron JR, Townsend MJ. Promising bone-related therapeutic targets for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):543-548.
2. Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm. 2011;17(9 Suppl B):S14-S18.
3. Zacharski LR, Brown FE, Memoli VA, et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immunol Immunopathol. 1992;63(2):155-162.
4. Busso N, Hamilton JA. Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2268-2279.
5. Hoppe B, Dörner T. Coagulation and the fibrin network in rheumatic disease: a role beyond haemostasis. Nat Rev Rheumatol. 2012;8(12):738-746.
6. Marty I, Péclat V, Kirdaite G, Salvi R, So A, Busso N. Amelioration of collagen-induced arthritis by thrombin inhibition. J Clin Invest. 2001;107(5):631-640.
7. Yang YH, Hall P, Little CB, et al. Reduction of arthritis severity in protease-activated receptor-deficient mice. Arthritis Rheum. 2005;52(4):1325-1332.
8. Flick MJ, LaJeunesse CM, Talmage KE, et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest. 2007;117(11):3224-3235.
9. Komáromi I, Bagoly Z, Muszbek L. Factor XIII: novel structural and functional aspects. J Thromb Haemost. 2011;9(1):9-20.
10. Bagoly Z, Koncz Z, Hársfalvi J, Muszbek L. Factor XIII, clot structure, thrombosis. Thromb Res. 2012;129(3):382-387.
11. Richardson VR, Cordell P, Standeven KF, Carter AM. Substrates of Factor XIII-A: roles in thrombosis and wound healing. Clin Sci (Lond). 2013;124(3):123-137.
12. Inbal A, Lubetsky A, Krapp T, et al. Impaired wound healing in factor XIII deficient mice. Thromb Haemost. 2005;94(2):432-437.
13. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII Deficiency. Semin Thromb Hemost. 2009;35(4):426-438.
14. Palumbo JS, Barney KA, Blevins EA, et al. Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost. 2008;6(5):812-819.
15. Suh TT, Holmbäck K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 1995;9(16):2020-2033.
16. Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res Ther. 2007;9(1):203.
17. Medicherla S, Ma JY, Mangadu R, et al. A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J Pharmacol Exp Ther. 2006;318(1):132-141.
18. Touaitahuata H, Cres G, de Rossi S, Vives V, Blangy A. The mineral dissolution function of osteoclasts is dispensable for hypertrophic cartilage degradation during long bone development and growth. Dev Biol. 2014;393(1):57-70.
19. Kwasny-Krochin B, Gluszko P, Undas A. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis. Thromb Res. 2010;126(1):e11-e16.
20. So AK, Varisco PA, Kemkes-Matthes B, et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost. 2003;1(12):2510-2515.
21. Busso N, Péclat V, Van Ness K, et al. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J Clin Invest. 1998;102(1):41-50.
22. Raghu H, Flick MJ. Targeting the coagulation factor fibrinogen for arthritis therapy. Curr Pharm Biotechnol. 2011;12(9):1497-1506.
23. Ho PP, Lee LY, Zhao X, et al. Autoimmunity against fibrinogen mediates inflammatory arthritis in mice. J Immunol. 2010;184(1):379-390.
24. Sánchez-Pernaute O, López-Armada MJ, Calvo E, et al. Fibrin generated in the synovial fluid activates intimal cells from their apical surface: a sequential morphological study in antigen-induced arthritis. Rheumatology (Oxford). 2003;42(1):19-25.
25. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3(8):1894-1904.
26. Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol. 1992;29(3):177-188.
27. Hethershaw EL, Cilia La Corte AL, Duval C, et al. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost. 2014;12(2):197-205.
28. Flick MJ, Du X, Degen JL. Fibrin(ogen)-alpha M beta 2 interactions regulate leukocyte function and innate immunity in vivo. Exp Biol Med (Maywood). 2004;229(11):1105-1110.
29. Flick MJ, Du X, Witte DP, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest. 2004;113(11):1596-1606.
30. Perez RL, Roman J. Fibrin enhances the expression of IL-1 beta by human peripheral blood mononuclear cells. Implications in pulmonary inflammation. J Immunol. 1995;154(4):1879-1887.
31. Marín F, Corral J, Roldán V, et al. Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. J Mol Cell Cardiol. 2004;37(3):699-704.
32. Muszbek L, Bereczky Z, Bagoly Z, Komáromi I, Katona É. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91(3):931-972.
33. Prince CW, Dickie D, Krumdieck CL. Osteopontin, a substrate for transglutaminase and factor XIII activity. Biochem Biophys Res Commun. 1991;177(3):1205-1210.
34. Ishii T, Ohshima S, Ishida T, et al. Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. Biochem Biophys Res Commun. 2004;316(3):809-815.
35. Ohshima S, Kobayashi H, Yamaguchi N, et al. Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum. 2002;46(4):1094-1101.
36. Yamamoto N, Sakai F, Kon S, et al. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest. 2003;112(2):181-188.
37. Ainola M, Mandelin J, Liljeström M, Konttinen YT, Salo J. Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis. Clin Exp Rheumatol. 2008;26(2):240-246.
38. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone. 2007;40(2):251-264.
39. Bezerra MC, Carvalho JF, Prokopowitsch AS, Pereira RM. RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz J Med Biol Res. 2005;38(2):161-170.
40. Geusens P. The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2012;4(4):225-233.
41. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford). 2008;47(11):1635-1640.
42. Walsh MC, Kim N, Kadono Y, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol. 2006;24:33-63.
43. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone. 2002;30(2):340-346.
44. Romas E, Sims NA, Hards DK, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol. 2002;161(4):1419-1427.
45. Kamijo S, Nakajima A, Ikeda K, et al. Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochem Biophys Res Commun. 2006;347(1):124-132.
46. Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 2001;159(5):1689-1699.
47. Stolina M, Schett G, Dwyer D, et al. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Res Ther. 2009;11(6):R187.
48. Hofbauer LC, Zeitz U, Schoppet M, et al. Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum. 2009;60(5):1427-1437.
49. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402(6759):304-309.
50. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203(12):2673-2682.
51. Aeschlimann D, Mosher D, Paulsson M. Tissue transglutaminase and factor XIII in cartilage and bone remodeling. Semin Thromb Hemost. 1996;22(5):437-443.
52. Al-Jallad HF, Nakano Y, Chen JL, McMillan E, Lefebvre C, Kaartinen MT. Transglutaminase activity regulates osteoblast differentiation and matrix mineralization in MC3T3-E1 osteoblast cultures. Matrix Biol. 2006;25(3):135-148.
53. Yin X, Chen Z, Liu Z, Song C. Tissue transglutaminase (TG2) activity regulates osteoblast differentiation and mineralization in the SAOS-2 cell line. Braz J Med Biol Res. 2012;45(8):693-700.
54. De Laurenzi V, Melino G. Gene disruption of tissue transglutaminase. Mol Cell Biol. 2001;21(1):148-155.
55. Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, Graham RM. Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem. 2001;276(23):20673-20678.
56. Nakano Y, Al-Jallad HF, Mousa A, Kaartinen MT. Expression and localization of plasma transglutaminase factor XIIIA in bone. J Histochem Cytochem. 2007;55(7):675-685.
57. Sárváry A, Szucs S, Balogh I, et al. Possible role of factor XIII subunit A in Fcgamma and complement receptor-mediated phagocytosis. Cell Immunol. 2004;228(2):81-90.
58. Jayo A, Conde I, Lastres P, Jiménez-Yuste V, González-Manchón C. Possible role for cellular FXIII in monocyte-derived dendritic cell motility. Eur J Cell Biol. 2009;88(8):423-431.
59. AbdAlla S, Lother H, Langer A, el Faramawy Y, Quitterer U. Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis. Cell. 2004;119(3):343-354.
60. Elli L, Ciulla MM, Busca G, et al. Beneficial effects of treatment with transglutaminase inhibitor cystamine on the severity of inflammation in a rat model of inflammatory bowel disease. Lab Invest. 2011;91(3):452-461.
61. Oh K, Park HB, Seo MW, Byoun OJ, Lee DS. Transglutaminase 2 exacerbates experimental autoimmune encephalomyelitis through positive regulation of encephalitogenic T cell differentiation and inflammation. Clin Immunol. 2012;145(2):122-132.